Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy

Indian Journal of Medical Research

Volumn 134, Issue 9, 2011, Pages 295-301

  Lakhan, Ram ^a   Kumari, Ritu ^a   Singh, Kavita ^a   Kalita, Jayanti ^a   Misra, Usha Kant ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytochrome; Drug refractory; Epilepsy; P450; Pharmacogenetics; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ADULT; ARTICLE; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; DRUG RESISTANCE, MULTIPLE; EPILEPSY; FEMALE; GENE FREQUENCY; HUMANS; INDIA; MALE; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054759834     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. WHO. World Health Organization: epilepsy: epidemiology, aetiology and prognosis. WHO Factsheet 2001: number 165.
2. Sisodiya SM Genetics of drug resistance. Epilepsia 2005; 46 (Suppl 10): 33-8.
3. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 2006; 10: 57-65.
4. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
5. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-85.
6. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007; 46: 271-9.
7. Yukawa E, Mamiya K. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. J Clin Pharm Ther 2006; 31: 275-82.
8. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs 102: 5507-12.
9. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 2006; 123: 665-70.
10. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287-91.
11. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2: 93-109.
12. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav 2009; 14: 78-82.
13. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1 N Engl J Med 2003; 348: 1442-8.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
15. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15.
16. Itoh K, Inoue K, Yanagiwara S, Kyoya H, Suzuki T. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Biol Pharm Bull 1999; 22: 77-9.
17. Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 1999; 65: 275-82.
18. Fritz S, Lindner W, Roots I, Frey B M, Küpfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-22.
19. Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit 2008; 30: 173-80.
20. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage. recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 26: 534-40.
21. Lamba JK, Dhiman RK, Kohli KK. CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther 2000; 68: 328-35.
22. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila. A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19: 170-9.
23. Zainuddin Z, Teh LK, Suhaimi AW, Ismail R. Malaysian. Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharm Ther 2006; 31: 187-91.
24. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 2003; 56: 331-3.
25. Simon C, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007; 115: 232-42.
26. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential Role of Sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in north Indian population. Brit J Clin Pharmacol 2009; 68: 214-20.
27. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001; 1: 204-10.
28. Schiller Y, Najjar Y. Quantifying the response to antiepileptic. drugs: effect of past treatment history. Neurology 2008; 70: 54-65.
29. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical. impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50: 1-23.